Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
4.000
-0.090 (-2.20%)
At close: May 4, 2026, 4:00 PM EDT
4.100
+0.099 (2.49%)
After-hours: May 4, 2026, 7:55 PM EDT
Zentalis Pharmaceuticals Employees
Zentalis Pharmaceuticals had 106 employees as of December 31, 2025. The number of employees decreased by 60 or -36.14% compared to the previous year.
Employees
106
Change (1Y)
-60
Growth (1Y)
-36.14%
Revenue / Employee
n/a
Profits / Employee
-$1,293,019
Market Cap
283.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 106 | -60 | -36.14% |
| Dec 31, 2024 | 166 | -2 | -1.19% |
| Dec 31, 2023 | 168 | 12 | 7.69% |
| Dec 31, 2022 | 156 | -21 | -11.86% |
| Dec 31, 2021 | 177 | 53 | 42.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| LENZ Therapeutics | 152 |
| Coherus Oncology | 147 |
| AC Immune | 122 |
| Foghorn Therapeutics | 106 |
| C4 Therapeutics | 104 |
| Editas Medicine | 87 |
| Protara Therapeutics | 46 |
ZNTL News
- 3 days ago - Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 17 days ago - Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 - GlobeNewsWire
- 24 days ago - What's Behind The Surge In Zentalis Stock? - Benzinga
- 25 days ago - Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - GlobeNewsWire
- 6 weeks ago - Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire